Sabby Management’s Nuvectis Pharma NVCT Stock Holding History

Sabby Management’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-587,452	Closed	-$4.41M	–	117
2022 Q4	$4.41M	Sell	587,452 -45,527	-7%	-$326K	3.86%	3
2022 Q3	$4.49M	Buy	+632,979	New	+$5.9M	5.66%	4

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sabby Management's NVCT Position: Q1 2023 in Review

Sabby Management sold out of Nuvectis Pharma (NVCT) in Q1 2023, closing a stake of 587,452 shares — an estimated $4.41M sold.

Sabby Management first reported a position in NVCT in Q3 2022 and held it in 2 quarters. The position peaked at $4.49M in Q3 2022. 12 funds tracked by Wall St. Rank hold NVCT as of Q1 2023.

Sabby Management reported no remaining Nuvectis Pharma position as of Q1 2023 after selling out during the quarter.
Sabby Management sold 587,452 Nuvectis Pharma shares in Q1 2023, an estimated $4.41M.
Sabby Management first reported a position in Nuvectis Pharma in Q3 2022 and held it in 2 quarters.
Sabby Management's Nuvectis Pharma position peaked at $4.49M in Q3 2022.
12 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2023.

Based on Sabby Management's 13F filing for Q1 2023, filed 15 May 2023.